Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models

Background: The multikinase inhibitor regorafenib, approved as second-line treatment for hepatocellular carcinoma (HCC) after sorafenib failure, may induce mitochondrial damage. BH3-mimetics, inhibitors of specific BCL-2 proteins, are valuable drugs in cancer therapy to amplify mitochondrial-depende...

Descripción completa

Detalles Bibliográficos
Autores principales: Cucarull, Blanca, Tutusaus, Anna, Subías, Miguel, Stefanovic, Milica, Hernáez-Alsina, Tania, Boix, Loreto, Reig, María, García de Frutos, Pablo, Marí, Montserrat, Colell, Anna, Bruix, Jordi, Morales, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073154/
https://www.ncbi.nlm.nih.gov/pubmed/32024199
http://dx.doi.org/10.3390/cancers12020332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073154/
https://www.ncbi.nlm.nih.gov/pubmed/32024199
http://dx.doi.org/10.3390/cancers12020332

Ejemplares similares